arrow
A

Amira Al-Uzri

arkansas children's hospital
H指数:23
被引数:2,070

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Population Pharmacokinetics and Exposure-Safety Analysis of Furosemide in Preterm Infants

呋塞米在早产儿中的群体药代动力学和暴露-安全性分析

2026-04-190
PRE
Correction: Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10‑Monohydroxy Derivative to Inform Dosing in Children with Obesity

更正:奥卡西平及其活性代谢物10-单羟基衍生物的群体药代动力学建模,以指导肥胖儿童用药剂量

2026-01-060
OAAI
Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10-Monohydroxy Derivative to Inform Dosing in Children with Obesity

奥卡沙比平及其活性代谢物10-单羟基衍生物的群体药代动力学建模,以指导肥胖儿童的剂量方案

2025-11-170
OAAI
Physiologically Based and Population Pharmacokinetic Modeling of Midazolam in Children With Obesity Using Real-World Data

基于生理学和群体药代动力学模型的肥胖儿童中效唑仑研究:基于真实世界数据

2025-05-130
OA
Cardiovascular and Thromboembolic Events in Children and Adults With Glomerular Disease: Findings From the Cure GlomeruloNephropathy (CureGN) Network

肾小球疾病患儿及成人患者的心血管和血栓栓塞事件:Cure GlomeruloNephropathy(CureGN)网络的研究发现

2024-07-200
OA
Patient-Reported Outcomes Over 24 Months in Pediatric CKD: Findings From the MyKidneyHealth Cohort Study
2023-08-012
OAAI
Sequential Stem Cell-Kidney Transplantation in Schimke Immuno-osseous Dysplasia
2022-06-1615
OA
Treatment Patterns Among Adults and Children With Membranous Nephropathy in the Cure Glomerulonephropathy Network (CureGN)
2019-12-0113
OAAI
Patient Recruitment into a Multicenter Randomized Clinical Trial for Kidney Disease: Report of the Focal Segmental Glomerulosclerosis Clinical Trial (FSGS CT)
2012-10-3011
OAAI